Wednesday, August 18, 2010 8:14:33 AM
Unregistered Sales of Equity Securities.
On June 21, 2010, Sino Green Land Corporation (the “Company”) issued an aggregate of 2,195,000 shares of its common stock, $0.001 par value per share (the “Common Stock”) to several of the Company’s non-executive employees and advisors (collectively, the “Non-Executive Grantees”) and an aggregate of 1,250,000 share of Common Stock to executive officers, including 500,000 shares to Anson Fong, 250,000 shares to Yan Pan and 500,000 shares to Xiong Luo (collectively, with the Non-Executive Grantees, the “Grantees”) in exchange for services provided to the Company by the Grantees. In addition, the Company’s board of directors resolved to issue 500,000 shares to Mr. Fong, 500,000 shares to Mr. Luo and 250,000 shares to Mr. Pan per quarter in each of the next three quarters. Several of the Grantees are non-U.S. persons (as that term is defined in Regulation S of the Securities Act of 1933 , as amended (the “Act”)). The Company issued Common Stock to these individuals in an offshore transaction in reliance upon an exemption provided by Regulation S promulgated under the Act and upon the exemption provided by Section 4(2) of the Act for the offer and sale of securities not involving a public offering. The Company issued Common Stock to U.S. Grantees in reliance on the exemption provided by Section 4(2) of the Act for the offer and sale of securities not involving a public offering.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) See Item 3.02 above, which is incorporated into this Item 5.02 by reference. Among the Grantees was Pan Yan, the Company’s Chief Operating Officer, whose shares of Common Stock are being granted pursuant to an Executive Employment Agreement, dated May 1, 2010, by and between the Company and Mr. Yan.
Recent SGLA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 11:54:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 10:10:45 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/12/2024 11:20:32 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 11:06:21 AM
- Form 10-KT - Transition reports [Rule 13a-10 or 15d-10] • Edgar (US Regulatory) • 09/28/2023 07:03:16 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/28/2023 03:55:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 10:52:40 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM